Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies. To accomplish this mission, we are dedicated to achieving these goals in Washington, D.C. and across the country.

Featured Blogs

PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs

Alex Schriver bio picture
Alex Schriver
PhRMA launched new advertisements urging Congress to mandate that rebates on medicines go directly to patients, not middlemen. The ad highlights how middlemen, like pharmacy benefit managers (PBMs) and insurers, use medicines as a profit center while driving up costs for patients and the health care system.
Chemist studying a pipette and test tube intently

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

Jocelyn Ulrich
Jocelyn Ulrich
Today, the Drug Price Competition and Patent Restoration Act - better known as the Hatch-Waxman Act - celebrates its 40th anniversary, marking four decades of success in fueling biopharmaceutical innovation while growing the U.S. generic market into the powerhouse it is today.

PhRMA urges HRSA not to impede new 340B pricing approaches to improve transparency and integrity

Drew Voytal
It’s past time to get 340B back on track and working for patients.

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.